Patent
Novel p2x7r antagonists and their use
Michael Boes
- 20 Jan 2012
11
TL;DR: In this article, the authors present an application for P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol 3-ylacetamide compounds.
read more
Abstract: The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Patent
Pyrimidine group-containing rigid conjugated macrocyclic compound, as well as preparation method and application thereof
Wusong Jin,Zhang Dengqing,Duoduo Xiao,Xianying Li,Beihua Chen,Ning Ruguang,Zhang Zhen +6 more
- 10 Jul 2013
TL;DR: In this article, a pyrimidine group-containing rigid conjugated macrocyclic compound is described, where the structural general formula of the compound is shown in the specification, wherein R is one or more independently selected from self-hydrophobic long-chain group, hydrophilic long chain group, chiral long chain groups, ester group, cyano-group, amino group, aryl and sulfydryl.
1
Patent
Compounds and compositions for treating conditions associated with sting activity
Roush William R,Venkatraman Shankar,Gary D. Glick,Seidel Hans Martin +3 more
- 28 May 2020
TL;DR: In this article, chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate) that inhibit (i.e., antagonize) Stimulator of Interferon Genes (STING) are presented.
1
Patent
Novel indole derivatives and their use in neurodegenerative diseases
Srinivasa R. Karra
- 16 Jun 2016
TL;DR: The present paper relates to indole compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P 2X7-related disorders as discussed by the authors.
1
Patent
Indole and azaindoles derivatives and their use in neurodegenerative diseases
Srinivasa R. Karra
- 24 Jun 2016
TL;DR: The present paper relates to indole and azaindole compounds of formula (I), and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P 2X7-related disorders as mentioned in this paper.
1
Patent
Method for synthesizing oxetane-3-carbaldehyde
Liu Jinwen,Wang Zhiping,Guo Shaoxiong,Yang Tingquan,Yang Fang,Song Yanmin +5 more
- 04 Dec 2013
Abstract: The invention relates to a method for synthesizing oxetane-3-carbaldehyde. According to the method, oxetan-3-ylmethanol is used as a starting material, and the oxetane-3-carbaldehyde is obtained after the Swern oxidation reaction, wherein the total yield is 85%. According to the method, various negative factors in the amplified production of the oxetane-3-carbaldehyde can be overcome. The method has the advantages of being low in raw material cost, short in route, free of dangerous reagents, high in yield and the like, and the product can be generated on a large scale, and is low in price and convenient to popularize.
References
•Book
Pharmaceutical Dosage Forms and Drug Delivery Systems
Howard C. Ansel,Loyd V. Allen,Nicholas G. Popovich +2 more
- 01 Apr 1990
TL;DR: The principles of dosage form design and development and novel and advanced dosage forms, delivery systems, and devices: radiopharmaceuticals products of biotechnology novel dosage forms and drug delivery technology are introduced.
Patent
P38 inhibitors and methods of use thereof
Mark Munson,David A. Mareska,Youngboo Kim,Robert D. Groneberg,James P. Rizzi,Martha Rodriguez,Ganghyeok Kim,Guy Vigers,Chang Rao,Devan Balachari,Darren Harvey +10 more
- 25 Feb 2004
TL;DR: In this article, an invention related to inhibitors of p38, and methods for producing these inhibitors are described. And pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38 are provided.
326
Patent
Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
Bang-Chi Chen,Ping Chen,John Hynes,Peter A. Kiener,Katerina Leftheris,Malinda Longphre,Derek J. Norris,Chennagiri R. Pandit,Steven H. Spergel,John S. Tokarski,Stephen T. Wrobleski,Hong Wu,Rulin Zhao +12 more
- 08 Feb 2001
TL;DR: In this paper, the use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed, and compounds useful as CBR modulators for treating respiratory and non-respiratory leukocyte activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of a and B is nitrogen; and R1-R6 are as defined in the specification, wherein R2 with R5 may form a ring, and/or two R4 groups may form six-membered a
186
Comprar Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems | Loyd V. Allen | 9781469855684 | Lippincott Williams & Wilkins
Loyd V. Allen
- 01 Jan 2013
TL;DR: Tienda online donde Comprar Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems al precio 67,20 € de Loyd V. Allen.
120
The P2X7 receptor as a therapeutic target.
Romeo Romagnoli,Pier Giovanni Baraldi,Olga Cruz-Lopez,Carlota Lopez-Cara,Delia Preti,Pier Andrea Borea,Stefania Gessi +6 more
TL;DR: The recent discoveries of novel P2X7 receptor-selective antagonists are described, along with their biological activity and therapeutic potential, which provide a novel therapeutic approach to the treatment of pain as well as neurodegenerative and inflammatory disorders.
93